Originally Posted by Tupelo3

Tozadenant (SYN115) has had a sort of strange history behind it the past few years. Biotie Therapies, the manufacturer, and their partner, UCB Pharma, completed a somewhat successful Phase 2b study almost two years ago (one dose level showed efficacy, the others didn't). They announced that they were preparing for a phase 3 study a few months later, and they also presented their results at several events. The past March, over a year later, UCB announced they were backing out and returned all drug rights to Biotie. As of their last report, Biotie has stated that they are still evaluating the best strategy for SYN115 to enhance shareholder value. They are also looking for another licensing partner. Makes me wonder if they will ever go forward with the next phase.